Gilead Sciences, Inc.
NEWS
The month of February ended with a flurry of clinical trial announcements. Here’s a look.
Shares of Forty Seven Inc. were up in premarket trading on rumors that Gilead Sciences has approached the company about a potential partnership or acquisition.
The randomized, open-label, multicenter studies will enroll about 1,000 patients mostly in Asia, as well as in countries that have had high numbers of diagnosed cases. The trials are planned to start in March.
The most recent BioSpace Ideal Employer Report revealed the impact of team dynamics on employees within life sciences organizations.
The company indicated then that it still believes all four HHS PrEP patents are invalid and should not have been granted.
Biopharma and life sciences companies strengthen their leadership teams and board with this week’s Movers & Shakers.
The trial’s goal is to test more than 700 patients infected with the coronavirus, but at this point, there have been fewer than 200 people recruited.
The BioSpace Ideal Employer Report examined aspects regarding the importance of culture within life sciences organizations.
These prices refer to the company’s list price. Most patients will not pay that price because of various forms of health insurance or patient assistance programs.
JOBS
IN THE PRESS